GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » NetraMark Holdings Inc (XCNQ:AIAI) » Definitions » Short Interest

NetraMark Holdings (XCNQ:AIAI) Short Interest


View and export this data going back to 2021. Start your Free Trial

What is NetraMark Holdings Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of NetraMark Holdings's Short Interest

For the Health Information Services subindustry, NetraMark Holdings's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NetraMark Holdings's Short Interest Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, NetraMark Holdings's Short Interest distribution charts can be found below:

* The bar in red indicates where NetraMark Holdings's Short Interest falls into.


NetraMark Holdings (XCNQ:AIAI) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » NetraMark Holdings Inc (XCNQ:AIAI) » Definitions » Short Interest
Comparable Companies
TSXV:THNK XCNQ:HS TSXV:ADK TSXV:NEWU TSXV:DOC TSXV:NURS TSXV:CDX XCNQ:CGN TSXV:XYBN XCNQ:UDOC GEHC VEEV TSE:2413 HQY ASX:PME RCM TXG DOCS PGNY TDOC
Traded in Other Exchanges
AINMF:USA
Address
1655 Dupont Street, Suite 101, Toronto, ON, CAN, M6P 3T1
Website
https://www.nurosene.com
NetraMark Holdings Inc is focused on the application of a totally unique Artificial Intelligence (AI) / Machine Learning (ML) solution targeted at the pharmaceutical industry in order to de-risk clinical trials. NetraMark has a proprietary technology that is capable of cutting through the combinatorial complexity that comes with dealing with heterogeneous patient populations to extract precisely defined personas of patients with respect to placebo and drug response, in addition to tolerability and adverse events. By using the client's own contemporaneous data, and having the capacity to learn from small data, the NetraAI tech extracts these personas to equip pharmaceutical companies with strategies to optimize their next trials for success.
Executives
Andrew Parks Director

NetraMark Holdings (XCNQ:AIAI) Headlines

No Headlines